International Journal of Pancreatology

, Volume 7, Issue 1–3, pp 177–185 | Cite as

Increased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapy

  • James L. Weese
  • Michael L. Nussbaum
  • Anthony R. Paul
  • Paul F. Engstrom
  • Lawrence J. Solin
  • Michael J. Kowalyshyn
  • John P. Hoffman


A prospective neoadjuvant trial utilizing chemotherapy (CTX) and radiotherapy (XRT) prior to pancreatectomy was established to determine the feasibility of resection after aggressive pretreatment and its effect on survival. Fifteen patients with pancreatic cancer (14 head, 1 body) and 1 patient with duodenal cancer, (with paraaortic adenopathy), were subjected to combination treatment with infusional 5-FU, bolus injection of mitomycin-C, and XRT (4 patients were treated off the protocol). Patients were restaged 3 wk after XRT, and those deemed resectable underwent a pancreatic resection. Three patients did not undergo exploration after the neoadjuvant therapy, although two of these were deemed resectable by CT scan. The remaining 13 patients underwent exploration and 10 underwent resection. Three did not undergo resection because of extrapancreatic disease, although their primary tumors were resectable. One patient had no residual tumor in the specimen. The others had residual tumor with evidence of necrosis and hyalinization, but all margins were free of tumor. There were two perioperative deaths from sepsis. Of the remaining patients who underwent resection, one died of a myocardial infarction at 9 mo. One patient died with recurrent disease at 19 mo. The remaining patients are alive 40, 32, 11, 11, 10, and 4 mo since diagnosis and are currently free of disease. Aggressive neoadjuvant chemoradiotherapy can be performed safely, allows successful resection, and may yield long-term survival or curve.

Key Words

Multimodality therapy pancreatectomy duodenal carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cancer statistics. CA 1989; 39: 3–20.Google Scholar
  2. 2.
    Gudjonsson B. Cancer of the pancreas, 50 years of surgery. Cancer 1987; 60: 2284–2303.PubMedCrossRefGoogle Scholar
  3. 3.
    Connolly MM, Dawson PJ, Michelassi F, et al. Survival in 1001 patients with carcinoma of the pancreas. Ann. Surg. 1987; 207: 366–370.Google Scholar
  4. 4.
    Morrow M, Hilaris B, and Brennan MF. Comparison of conventional surgical resection, radioactive implantation, and bypass procedures for exocrine carcinoma of the pancreas. Ann. Surg. 1984; 199: 1–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Gall FP and Kocherling F. The problems of radical surgery in pancreatic cancer and its implications for a combined-treatment approach. Recent Results Cancer Res. 1988; 110: 79–86.PubMedGoogle Scholar
  6. 6.
    Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann. Surg. 1986; 203: 77–81.PubMedCrossRefGoogle Scholar
  7. 7.
    Warshaw AL and Swanson RS. What’s new in general surgery—pancreatic cancer in 1988. Ann. Surg. 1988; 208: 541–553.PubMedCrossRefGoogle Scholar
  8. 8.
    Gastrointestinal Tumor Study Group. Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 1979; 5: 1643–1647.Google Scholar
  9. 9.
    Child CG, Frey CF. Pancreaticoduodenectomy—surgical grand rounds—University of Michigan. Surg. Clin. North Am. 1966; 46: 1201–1213.Google Scholar
  10. 10.
    Borgelt BB. Radiation therapy with or without gold grain implant or neutron beam for unresectable adenocarcinoma of the pancreas. Pancreatic Cancer: New Directions in Therapeutic Management, vol. 7, Cohn I Jr. ed., Masson Publishing, New York, 1981; 55–62.Google Scholar
  11. 11.
    Borgelt BB, Dobelbower RR, and Strubler KA. Betatron therapy for unresectable pancreatic cancer. Am. J. Surg. 1978; 135: 76–80.PubMedCrossRefGoogle Scholar
  12. 12.
    Pilepich MV and Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer 1980; 46: 1945–1949.PubMedCrossRefGoogle Scholar
  13. 13.
    Sischy B, Remington JH, Sobel SH, et al. Treatment of carcinoma of the rectum and squamous carcinoma of the anus by combination chemotherapy radiation and operation. Surg. Gynecol. Obstet. 1980; 151: 369–371.PubMedGoogle Scholar
  14. 14.
    Byfield JE. Infusional 5-FU and X-ray therapy for nonresectable esophageal cancer. Cancer 1980; 45: 703–708.PubMedCrossRefGoogle Scholar
  15. 15.
    Byfield JE. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5:fluorouracil or ftorafur and X-rays. Int. J. Radiat. Oncol. Biol. Phys. 1982; 8: 1923–1933.PubMedGoogle Scholar
  16. 16.
    Thomas PRM, Lindblad AS, Stablein DM, et al. Toxicity associated with adjuvant postoperative therapy for adenocarcinoma of the rectum. Cancer 1986; 57: 1130–1134.PubMedCrossRefGoogle Scholar
  17. 17.
    Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59: 2006–2010.CrossRefGoogle Scholar
  18. 18.
    Nagai H, Kuroda A, and Morioka Y. Lymphatic and local spread of T1 and T2 pancreatic cancer. Ann. Surg. 1986; 204: 65–71.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 1990

Authors and Affiliations

  • James L. Weese
    • 1
  • Michael L. Nussbaum
    • 1
  • Anthony R. Paul
    • 2
  • Paul F. Engstrom
    • 2
  • Lawrence J. Solin
    • 3
  • Michael J. Kowalyshyn
    • 4
  • John P. Hoffman
    • 1
  1. 1.Departments of Surgical OncologyFox Chase Cancer CenterPhiladelphia
  2. 2.Medical OncologyFox Chase Cancer CenterPhiladelphia
  3. 3.Radiation OncologyFox Chase Cancer CenterPhiladelphia
  4. 4.PathologyFox Chase Cancer CenterPhiladelphia

Personalised recommendations